New research suggests that ketamine nasal spray may prove a safe and effective treatment for refractory chronic migraine.
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).
New data released by Sunstone Therapies shows positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD).
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
Cybin Inc.
PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic...
Lucy Scientific Discovery is partnering with non-profit organization that advocates for legal access to psilocybin therapy for Canadians, TheraPsil, to advance medical access and research.
A UK Parliamentary debate on 18 May saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1...